EcoDrugPlus

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSPEMG00000028345
Gene Symbol: CHRM4
3 Cross references
184 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSPEMG00000015010
Gene Symbol: CHRNB2
3 Cross references
197 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSPEMG00000006587
Gene Symbol: CHRNB4
3 Cross references
198 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5

Ensembl ID : ENSPEMG00000019579
Gene Symbol: CHRM5
1 Cross references
263 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha Polypeptide 3

Ensembl ID : ENSPEMG00000019893
Gene Symbol: CHRNA3
1 Cross references
207 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha Polypeptide 4

Ensembl ID : ENSPEMG00000003527
Gene Symbol: CHRNA4
1 Cross references
204 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha Polypeptide 7

Ensembl ID : ENSPEMG00000015506
Gene Symbol: CHRNA7
1 Cross references
243 Possible Orthologues:

Churchill Domain Containing 1

Ensembl ID : ENSPEMG00000012288
Gene Symbol: CHURC1
3 Cross references
210 Possible Orthologues:

Chymase 1, Mast Cell

Ensembl ID : ENSPEMG00000010040
Gene Symbol: CMA1
1 Cross references
292 Possible Orthologues:

Coagulation Factor Ii (Thrombin) Receptor

Ensembl ID : ENSPEMG00000025363
Gene Symbol: F2R
1 Cross references
327 Possible Orthologues:

Coagulation Factor Ii, Thrombin

Ensembl ID : ENSPEMG00000018118
Gene Symbol: F2
3 Cross references
85 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSPEMG00000005387
Gene Symbol: F3
3 Cross references
243 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).